PT-141
LIBIDO/EDQuick Specifications
| Vial Size | 5MG |
|---|---|
| BAC Water | 1ML |
| Amount Per Unit | 0.05MG PER UNIT |
| Recommended Dose | 500MCG (10 UNITS) |
| Frequency | AS NEEDED (2 HOURS BEFORE SEXUAL ACTIVITY) |
| Injection Type | SUBCUTANEOUS |
| Timing | Not To Exceed 20 Units (Consult With Doctor) |
Research Overview
SIGNALS CENTRAL NERVOUS SYSTEM TO ENHANCE BLOOD FLOW, AROUSAL AND LIBIDO IN MEN AND WOMEN
How It Works
Melanocortin Receptor Agonism
PT-141 (bremelanotide) is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) that acts as an agonist at melanocortin receptors MC3R and MC4R. These receptors are expressed in the hypothalamus and limbic system — brain areas governing sexual response and arousal.
Central Nervous System Mechanism
Unlike phosphodiesterase inhibitors (e.g., sildenafil) which act peripherally on blood vessels, PT-141 works centrally through the nervous system. It activates the hypothalamic melanocortin pathway to directly influence sexual motivation and arousal — a fundamentally different mechanism.
FDA-Approved Foundation
Bremelanotide (PT-141) received FDA approval as Vyleesi in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, validating its central melanocortin mechanism. Research continues to explore applications in male sexual dysfunction.
PT-141: 5mg information on this page is for research and educational purposes only. This content is not FDA-approved, does not constitute medical advice, and should not be used to guide personal health decisions. Consult a qualified healthcare professional before using any research compound.
Dose Calculator
Enter your target dose to calculate the volume to draw.
Recommended dose: 500MCG (10 UNITS)